SCHEMBL1199130

SCHEMBL1199130

FC(F)c1sc(-c2cccc(C(F)(F)F)c2)nc1COC1CCCCO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GRIN1 Q05586 3/20 0.37
GRIN2B Q13224 3/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4C Q9H3R0 1/20 0.35
AR P10275 1/20 0.34
ALPL P05186 1/20 0.34
ALPI P09923 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PIM1 P11309 3/20 0.34
PIM2 Q9P1W9 1/20 0.34
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876163 0.88 KDM4C (0.35) MAPTMEN1KMT2APPARGPPARA
SCHEMBL1199248 0.87 GRIN1 (0.38) MAPTMEN1KMT2AGRIN1GRIN2B
SCHEMBL1197624 0.87 MEN1 (0.41) MAPTMEN1KMT2AGRIN1GRIN2B
SCHEMBL1198600 0.87 GRIN1 (0.38) MAPTMEN1KMT2AGRIN1GRIN2B
SCHEMBL1198888 0.86 GRIN1 (0.37) MAPTMEN1KMT2AGRIN1GRIN2B
SCHEMBL1199541 0.85 PPARG (0.40) MAPTMEN1KMT2AGRIN1GRIN2B
SCHEMBL1198819 0.79 ALDH1A1 (0.44) MAPTMEN1KMT2AGRIN1GRIN2B
SCHEMBL2431523 0.75 GRIN1 (0.42) MAPTGRIN1GRIN2BKDM4CLMNA
SCHEMBL4807205 0.75 PPARD (0.37) MAPTMEN1KMT2APPARGPPARA
SCHEMBL12890243 0.75 AR (0.47) MEN1KMT2AGRIN1GRIN2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MAPT 4667/4885MEN1 2661/4885KMT2A 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.